High density lipoproteins and arteriosclerosis role of cholesterol efflux and reverse cholesterol transport

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 1, 2001, Pages 13-27

  Von Eckardstein, Arnold ^a   Nofer, Jerzy Roch ^a   Assmann, Gerd ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

ABC transporter; Apolipoproteins; Lipases; Lipid transfer proteins; Tangier disease

Indexed keywords

ABC TRANSPORTER; CARRIER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL LIPASE;

ARTERIOSCLEROSIS; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; HUMAN; LIPID METABOLISM; LIPID TRANSPORT; LIPOLYSIS; METABOLIC ACTIVATION; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEROIDOGENESIS; TANGIER DISEASE;

EID: 0035170229     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.21.1.13     Document Type: Review

References (216)

1. Current concepts: High density lipoproteins-the clinical implications of recent studies
2. High density lipoproteins in health disease
3. Atheroprotective mechanisms of HDL
4. Prevention of coronary heart disease by raising of high density lipoprotein cholesterol?
5. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species including humans
6. The plasma lecithin: Cholesterol acyltransferase reaction
7. Prevalence of risk factors in men with premature coronary artery disease
8. Short-term prognostic value of lipid measurements for coronary events in patients with angina pectoris
9. Coronary heart disease: Reducing the risk: The scientific background to primary and secondary prevention of coronary heart disease: A worldwide view
10. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults
11. New perspectives on the management of low levels of high density lipoprotein cholesterol
12. Familial lipoprotein disorders in patients with coronary heart disease
13. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment
14. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
15. Epidemiological aspects of high density lipoprotein cholesterol
16. An ecological study of determinants of coronary heart disease rates: A comparison of Czech, Bavarian Israeli men
17. Associations of obesity markers, insulin and sex hormones with HDL-cholesterol levels in Turkish and German individuals
18. Relation of components of insulin resistance to coronary disease risk
19. Systemic inflammatory parameters in patients with atherosclerosis of the coronary peripheral arteries
20. Cholesterol reduction yields clinical benefit: Impact of statin trials
21. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
22. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)
23. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study
24. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group
25. Physiological role and clinical relevance of high-density lipoprotein subclasses
26. Pre-β HDL: Structure metabolism
27. Molecular physiology of reverse cholesterol transport
28. A solely apolipoprotein E containing plasma lipoprotein with electrophoretic gamma-mobility takes up cellular cholesterol
29. Characterization of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid
30. Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma
31. Comparison of apo A-I-containing subpopulations of dog plasma and prenodal peripheral lymph: Evidence for alteration in subpopulations in the interstitial space
32. Concentrations of electrophoretic and size subclasses of apolipoprotein A-I-containing particles in human peripheral lymph
33. Remodeling of high density lipoproteins by plasma factors
34. Secretion of pre-beta-migrating apo A-I by cynomolgus monkey hepatocytes in culture
35. Apical secretion of apolipoproteins from enterocytes
36. Dissociation of high density lipoprotein precursors from apolipoprotein B-containing lipoproteins in the presence of unesterified fatty acids and a source of apolipoprotein A-I
37. Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins
38. Increased pre-β-HDL levels, cholesterol efflux, and LCAT mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes
39. 1-HDL
40. Increased pre-β-high density lipoprotein, apolipoprotein A-I, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein A-I transgenes
41. 2
42. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids
43. Apolipoprotein A-I-cell membrane interaction: Extracellular assembly of heterogeneous nascent HDL particles
44. Role of free apolipoprotein A-I in cholesterol efflux: Formation of pre-β-migrating high density lipoprotein particles
45. Cholesterol efflux to apolipoprotein A-I involves endocytosis resecretion in a calcium-dependent pathway
46. Intracellular processing of endocytosed triglyceride-rich lipoproteins comprises both recycling degradation
47. Tangier disease: A disorder of intracellular membrane traffic
48. Mutations in ABC1 in Tangier disease and familial high density lipoprotein deficiency
49. The gene encoding ATP binding cassette transporter 1 is mutated in Tangier disease
50. Tangier disease is caused by mutations in the gene encoding ATP binding cassette transporter 1
51. The Tangier disease gene product controls the cellular apolipoprotein-mediated lipid removal pathway
52. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1
53. Molecular cloning of the human ATP binding cassette transporter 1 (hABC1): Evidence for sterol-dependent regulation in macrophages
54. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport
55. Regulation of the concentration of pre high density lipoprotein in normal plasma by cell membranes lecithin:Cholesterol acyltransferase
56. Remodelling of reconstituted high density lipoproteins by lecithin:Cholesterol acyltransferase
57. Lipid-free apolipoprotein (apo) A-I is converted into alpha-migrating high density lipoproteins by lipoprotein depleted plasma of normolipidemic donors and apoA-I-deficient patients but not of Tangier disease patients
58. 2 during the action of LCAT: The role of triglyceride-rich lipoproteins
59. The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: Evidence for particle fusion
60. Targeted mutation of plasma phospholipid transfer protein markedly reduces high density lipoprotein levels
61. Charting the fate of the good cholesterol: Identification and characterization of the high density lipoprotein receptor SR-BI
62. The role of high-density lipoprotein receptor SR-BI in cholesterol metabolism
63. Apolipoprotein E and atherosclerosis
64. George Lyman Duff Memorial Lecture: Lipid transfer proteins, HDL metabolism and atherogenesis
65. Hepatic lipase: New insights from genetic metabolic studies
66. Hepatic lipase and HDL metabolism
67. Endothelial lipase: A new member of the triglyceride lipase gene family
68. Cubilin, a high density lipoprotein receptor
69. The intrinsic factor-vitamin B-12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein
70. Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis
71. Acyl coenzyme A: Cholesterol acyltransferase
72. Intracellular cholesterol transport
73. Intracellular cholesterol transport
74. cAMP stimulates cholesteryl ester clearance to high density lipoproteins in J774 macrophages
75. Cholesterol efflux from macrophages and other cells
76. Cell cholesterol efflux: Integration of old and new observations provides new insights
77. Membrane microdomains and caveolae
78. Cholesterol and the Golgi apparatus
79. Functional rafts in cell membranes
80. Protein sorting by transport vesicles
81. Monensin and brefeldin A inhibit high density lipoprotein mediated cholesterol efflux from cholesterol-enriched cells: Implications for intracellular cholesterol trafficking
82. Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins
83. Cholesterol efflux mediated by apolipoproteins is an active cellular process distinct from efflux mediated by passive diffusion
84. Decreased reverse cholesterol transport from Tangier disease fibroblasts: Acceptor specificity and effect of brefeldin on lipid efflux
85. Interaction of free apolipoproteins with macrophages: Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol
86. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol
87. Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides
88. Apolipoprotein-mediated plasma membrane microsolubilization: Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol phospholipid
89. Intracellular cholesterol transport in synchronized human skin fibroblasts
90. Apolipoprotein A-I efficiently binds to and mediates cholesterol and phospholipid efflux from human but not from rat aortic smooth muscle cells
91. Independent regulation of cholesterol incorporation into free apolipoprotein-mediated cellular lipid efflux in rat vascular smooth muscle cells
92. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease
93. The high density lipoprotein- and apolipoprotein A-I-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects
94. Plasma membrane caveolae mediate the efflux of cellular free cholesterol
95. Cholesterol efflux from adipose cells is coupled to diacylglycerol production and protein kinase C activation
96. Protein kinase C as a mediator of high density lipoprotein dependent efflux of intracellular cholesterol
97. Induction of cholesterol efflux to lipid-free apolipoprotein A-I by cAMP
98. Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors
99. The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines
100. ABCI promotes engulfment of apoptotic cells transbilayer redistribution of phosphatidylserine
101. Lecithin:Cholesterol acyltransferase reaction on cellular lipid released by free apolipoprotein-mediated efflux
102. Scavenger receptor B1 promotes high density lipoprotein-mediated cellular cholesterol efflux
103. Scavenger receptor B1 mediates free cholesterol flux independent of HDL tethering to the cell surface
104. 3 stimulates multiple signaling pathways in human skin fibroblasts
105. Defective regulation of phosphatidylcholine-specific phospholipases C and D in a kindred with Tangier disease: Evidence for the involvement of phosphatidylcholine breakdown in HDL-mediated cholesterol efflux mechanisms
106. 2+ in cultured fibroblasts
107. High density lipoproteins and low density lipoprotein mediated signal transduction in cultured human skin fibroblasts
108. HDL-mediated efflux of intracellular cholesterol is impaired in fibroblasts from Tangier disease patients
109. Activation of phosphatidylinositol-specific phospholipase C in response to HDL3 and LDL is markedly reduced in cultured fibroblasts from Tangier patients
110. Activation of phosphatidylinositol-specific phospholipase C (PI-PLC) by HDL-associated lysosphingolipids: Involvement in mitogenesis but not in cholesterol efflux
111. Neutral cholesterol esterase activity in macrophages and its enhancement by cyclic AMP-dependent protein kinase
112. Complete genomic sequence of the human ABCA1 gene: Analysis of the human mouse ATP biding cassette A promoter
113. Good cholesterol news
114. ABC1, an ATP binding cassette transporter required for phagocytosis of apoptotic cells, generates a regulated anion flux after expression in Xenopus laevis oocytes
115. Interleukin 1β secretion is impaired by inhibitors of the ATP binding cassette transporter ABC1
116. Lipid translocation across the plasma membrane of mammalian cells
117. Sterol-dependent transactivation of the ABC1 promoter by LXR/RXR: LXRs transactivate ABC1 promotor
118. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers
119. Specific binding of apoA-I, enhanced cholesterol efflux and altered plasma membrane morphology in cells expressing ABC1
120. ABCA1 is the cAMP-inducible receptor that mediates cholesterol secretion from macrophages
121. Transport of lipids from Golgi to plasma membrane is defective in Tangier disease: Patients Abc1-deficient mice
122. Intracellular CFTR: Localization function
123. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice
124. Identification of a novel human sterol-sensitive ATP-binding cassette transporter (ABCA7)
125. Apolipoprotein E secretion by macrophages: Its potential functions
126. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation
127. Treatment of severe hyperlipidemia in apolipoprotein E-deficient mice by bone marrow transplantation
128. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoproteinE-null mice
129. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages
130. Independent pathways for secretion of free cholesterol and apolipoprotein E by macrophages
131. Synthesis and secretion of apo E in thioglycolate-elicited mouse peritoneal macrophages: Effect of cholesterol efflux
132. 3
133. Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors
134. Phenotype-dependent differences in apolipoprotein E metabolism and cholesterol homeostasis in human monocyte-derived macrophages
135. Apolipoprotein A-I promotes cholesterol release and apolipoprotein E recruitment from THP-1 macrophage like foam cells
136. Apolipoprotein A-I stimulates secretion of apolipoprotein E by foam cell macrophages
137. Apolipoprotein E-dependent cholesterol efflux from macrophages: Kinetic study and divergent mechanisms for endogenous versus exogenous apolipoprotein E
138. Endogenous apolipoprotein E modulates cholesterol efflux and cholesterol ester hydrolysis mediated by high-density lipoprotein-3 and lipid-free apolipoproteins in mouse peritoneal macrophages
139. High density lipoprotein receptors, binding proteins, and ligands
140. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor
141. The class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into caveolae
142. The efficient cellular uptake of high density lipoprotein lipids via scavenger receptors class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain
143. Comparison of class B scavenger receptors, CD36 and scavenger receptor BI (SR-BI) shows that both receptors mediate high density lipoprotein-cholesteryl ester selective uptake but SR-BI exhibits a unique enhancement of cholesteryl ester uptake
144. Mechanism of scavenger receptor class B type I-mediated selective uptake of cholesteryl esters from high density lipoprotein to adrenal cells
145. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptors BI
146. Remodeling of HDL by CETP in vivo and by CETP hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I
147. Decreased selective uptake of high density lipoprotein cholesteryl esters in apolipoprotein E knockout mice
148. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology
149. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels
150. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene
151. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse
152. In vivo regulation of scavenger receptor BI and the selective uptake of high density lipoprotein cholesteryl esters in rat liver parenchymal and Kupffer cells
153. Cholesteryl ester transfer protein and its plasma regulator: Lipid transfer inhibitor protein
154. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency
155. Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F
156. Sterol regulatory element binding protein-1 activates the cholesteryl ester transfer protein gene in vivo but is not required for sterol up-regulation of gene expression
157. Characterization of a cholesterol response element (CRE) in the promoter of the cholesteryl ester transfer protein gene: Functional role of the transcription factors SREBP-1a,-2, and YY1
158. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element
159. Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles
160. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol: Studies in normotriglyceridemia and moderate hypertriglyceridemia
161. Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein
162. Cholesteryl ester transfer protein and atherosclerosis
163. Atherosclerotic disease in marked hyperalphalipoproteinemia: Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase
164. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia
165. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene
166. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels
167. Association of cholesteryl ester protein TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: The Framingham Study
168. Vaccine induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis
169. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein
170. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene
171. Increased atherosclerosis in apoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression
172. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice
173. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein
174. Hepatic lipase deficiency
175. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis
176. Hepatic lipase hydrolysis of lipid monolayers: Regulation by apolipoproteins
177. ApoA-II maintains HDL levels in part by inhibition of hepatic lipase: Studies in apoA-II and hepatic lipase double knockout mice
178. High-density lipoprotein 3 receptor-dependent endocytosis pathway in a human hepatoma cell line (HepG2)
179. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate
180. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins
181. Low hepatic lipase activity is a risk factor for coronary artery disease
182. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E deficient mice
183. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice
184. A novel endothelial-derived lipase that modulates HDL metabolism
185. Cloning of unique lipase from endothelial cells extends the lipase gene family
186. The intrinsic factor-vitamin B12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins
187. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
188. Familial high density lipoprotein deficiency: Tangier disease
189. Metabolism of apoE-free high density lipoproteins in rat hepatoma cells: Evidence for a retroendocytic pathway
190. Retroendocytosis of high density lipoproteins by the human hepatoma cell line, HepG2
191. Defective HDL particle uptake in ob/ob hepatocytes causes decreased recycling, degradation, and selective lipid uptake
192. Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-1 and ApoA-II, and decreased ApoA-I mRNA in ob/ob mice: Possible role of leptin in stimulation of HDL turnover
193. Familial HDL deficiency syndromes
194. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice
195. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice
196. Reverse cholesterol transport in plasma of patients with different forms of familial high density lipoprotein deficiency
197. Effects of genotype and diet on cholesterol efflux into plasma and lipoproteins of normal, apolipoprotein A-I-, and apolipoprotein E-deficient mice
198. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI
199. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits
200. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse
201. Apo A-I inhibits foam cell formation in apo E-deficient mice after monocyte adherence to endothelium
202. Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models
203. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice
204. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI
205. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: Potential reverse cholesterol transport in humans
206. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV
207. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apoA-IV
208. The molecular pathology of lecithin:Cholesterol acyltransferase (LCAT) deficiency syndromes
209. Homozygous Tangier disease and cardiovascular disease
210. Targeted disruption of the mouse lecithin:Cholesterol acyltransferase (LCAT) gene: Generation of a new animal model for human LCAT deficiency
211. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase
212. Overexpression of lecithin:Cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis
213. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice
214. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II
215. Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: Evidence of a potentially relevant species-specific interaction with diet
216. Decreased susceptibility to diet induced atherosclerosis in human apolipoprotein A-II transgenic mice